Stammdaten
Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
Unternehmen & Branche
| Name | NEONC TECHNOLOGIES HOLDINGS, INC. |
|---|---|
| Ticker | NTHI |
| CIK | 0001979414 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 84,1 Mio. USD |
| Beta | 3,60 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 39,990 | -62,146,210 | -3.20 | 2,823,634 | -17,507,729 |
| 2025-09-30 | 10-Q | 39,990 | -8,615,920 | -0.45 | 4,082,916 | -11,814,270 |
| 2025-06-30 | 10-Q | 39,990 | -5,680,170 | -0.30 | 2,988,187 | -11,815,494 |
| 2025-03-31 | 10-Q | 39,990 | -32,326,016 | -2.10 | 8,441,691 | -9,623,645 |
| 2024-12-31 | 10-K | 83,000 | -11,898,464 | -0.69 | 3,417,241 | -5,504,961 |
| 2024-09-30 | 10-Q | 63,000 | -2,184,500 | -0.12 | -5,267,392 | |
| 2024-06-30 | 10-Q | 20,000 | -4,522,006 | -0.27 | -6,208,513 | |
| 2024-03-31 | 10-Q | 43,000 | -2,938,976 | -0.18 | -16,927,229 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-28 | Heshmatpour Amir F | Director, Officer, 10% Owner, President | Open Market Purchase | 10,000 | 4.52 | 45,180.00 | +154,4% | |
| 2026-04-23 | Neman-Ebrahim Yousha | Officer, Chief Clinical Officer | Open Market Purchase | 500 | 4.88 | 2,440.00 | +8,3% | |
| 2026-04-23 | Heshmatpour Amir F | Director, Officer, 10% Owner, President | Open Market Purchase | 10,000 | 4.90 | 49,000.00 | +167,4% | |
| 2026-04-10 | Heshmatpour Amir F | Director, Officer, 10% Owner, President | Open Market Purchase | 10,000 | 4.90 | 48,950.00 | +167,2% | |
| 2026-04-09 | Heshmatpour Amir F | Director, Officer, 10% Owner, President | Open Market Purchase | 5,000 | 5.19 | 25,950.00 | +88,7% | |
| 2026-04-09 | SUH, DAVID JR. | Officer, Chief Accounting Officer | Open Market Purchase | 200 | 5.00 | 1,000.00 | +3,4% | |
| 2026-04-08 | Heshmatpour Amir F | Director, Officer, 10% Owner, President | Open Market Purchase | 10,000 | 5.61 | 56,050.00 | +191,5% | |
| 2026-04-06 | Heshmatpour Amir F | Director, Officer, 10% Owner, President | Open Market Purchase | 5,000 | 6.32 | 31,600.00 | +108,0% | |
| 2026-04-02 | Heshmatpour Amir F | Director, Officer, 10% Owner, President | Open Market Purchase | 20,000 | 6.09 | 121,798.00 | +416,1% | |
| 2025-11-24 | Heshmatpour Amir F | Director, Officer, 10% Owner, President | Open Market Purchase | 6,000 | 6.51 | 39,060.00 | +133,5% | |
| 2025-11-21 | Heshmatpour Amir F | Director, Officer, 10% Owner, President | Open Market Purchase | 20,000 | 5.98 | 119,600.00 | +408,6% | |
| 2025-11-21 | Heshmatpour Amir F | Director, Officer, 10% Owner, President | Open Market Purchase | 4,000 | 6.50 | 26,000.00 | +88,8% | |
| 2025-11-20 | Neman-Ebrahim Yousha | Officer, Chief Clinical Officer | Open Market Purchase | 1,100 | 6.69 | 7,359.00 | +25,1% | |
| 2025-05-23 | Heshmatpour Amir F | Director, Officer, President | Open Market Purchase | 2,000 | 7.39 | 14,785.00 | +50,5% | |
| 2025-05-22 | GARNETT KEITHLY | Officer, CFO | Open Market Purchase | 675 | 7.29 | 4,920.75 | +16,8% | |
| 2025-05-19 | GARNETT KEITHLY | Officer, CFO | Open Market Purchase | 135 | 7.23 | 976.05 | +3,3% | |
| 2025-05-16 | Heshmatpour Amir F | Director, Officer, President | Open Market Purchase | 3,510 | 16.87 | 59,221.07 | +202,3% | |
| 2025-05-15 | Heshmatpour Amir F | Director, Officer, President | Open Market Purchase | 1,500 | 7.30 | 10,945.05 | +37,4% | |
| 2025-05-14 | Heshmatpour Amir F | Director, Officer, President | Open Market Purchase | 1,000 | 7.27 | 7,267.00 | +24,8% | |
| 2025-05-13 | GARNETT KEITHLY | Officer, CFO | Open Market Purchase | 90 | 7.01 | 631.11 | +2,2% | |
| 2025-05-13 | GARNETT KEITHLY | Officer, CFO | Open Market Purchase | 90 | 7.01 | 631.11 | +2,2% | |
| 2025-05-13 | Heshmatpour Amir F | Director, Officer, President | Open Market Purchase | 990 | 7.01 | 6,941.78 | +23,7% | |
| 2025-05-12 | Heshmatpour Amir F | Director, Officer, President | Open Market Purchase | 1,400 | 7.23 | 10,123.96 | +34,6% | |
| 2025-05-11 | Heshmatpour Amir F | Director, Officer, President | Open Market Purchase | 1,600 | 7.51 | 12,016.00 | +41,1% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.